A first-in-human study to learn about how safe BAY 3375968 is, how it moves into, through, and out of the body, and to find its best dose when given alone or with pembrolizumab in participants with advanced solid tumors

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505594-32-00

Acronym

21820

Enrollment

103

Registered

2023-12-11

Start date

2024-02-20

Completion date

Unknown

Last updated

2025-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, France, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026